Early Coadministration of Clonazepam With Sertraline for Panic Disorder
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
BACKGROUND: There is debate about combining benzodiazepines with selective serotonin reuptake inhibitors in the acute treatment of panic disorder. Although this medication combination is widely used in clinical practice, there is no well-tested, optimal method of coadministering these medications for the treatment of panic disorder. The purpose of this study was to test the efficacy of early coadministration of clonazepam with sertraline in the treatment of panic disorder. METHODS: Fifty patients with panic disorder were randomized into a double-blind clinical trial. Patients received open-label sertraline for 12 weeks (target dose, 100 mg/d), and in addition were randomized to groups receiving either 0.5 mg of active clonazepam 3 times daily or placebo clonazepam for the first 4 weeks of the trial. The clonazepam dose was then tapered during 3 weeks and discontinued. RESULTS: Thirty-four (68%) of 50 patients completed the trial. Drop-out rates were similar in the sertraline/placebo vs the sertraline/clonazepam group (38% vs 25%) (P =.5). An intent-to-treat analysis (on last observation carried forward data) revealed a much greater proportion of responders in the sertraline/clonazepam compared with the sertraline/placebo group at the end of week 1 of the trial (41% vs 4%) (P =.003). There was also a significant between-group difference at the end of week 3 with 14 (63%) of 22 of the sertraline/clonazepam group responding to treatment vs 8 (32%) of 25 of the sertraline/placebo group (P =.05). This difference was not observed at other times during the trial. CONCLUSION: These data indicate that rapid stabilization of panic symptoms can be safely achieved with a sertraline/clonazepam combination, supporting the clinical utility of this type of regimen for facilitating early improvement of panic symptoms relative to sertraline alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The assessment of anxiety states by rating
HAMILTON, M. (1959) · British Journal of Medical Psychology · doi:10.1111/j.2044-8341.1959.tb00467.x · Cited by 11,455
Multicenter Collaborative Panic Disorder Severity Scale
Shear, M. K., Brown, T. A., Barlow, D. H., Money, R., Sholomskas, D. E., Woods, S. W., Gorman, J. M., & Papp, L. A. (1997) · American Journal of Psychiatry · doi:10.1176/ajp.154.11.1571 · Cited by 1,001
Self-citationBarlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Self-citationOn choosing a test statistic in multivariate analysis of variance
Olson, C. L. (1976) · Psychological Bulletin · doi:10.1037/0033-2909.83.4.579 · Cited by 649 · cited 1×
“All other continuous efficacy measures were subjected to an omnibus multivariate analysis of variance (MANOVA) (general linear model),(18) using the Pillais trace statistic.(19) The MANOVA was considered a conservative first step in establishing the presence of an effect in the whole data set, since it protects agains…”
Method
Cited by
Katzman, M. A., Bleau, P., Blier, P., Chokka, P., Kjernisted, K., Van Ameringen, M., & the Canadian Anxiety Guidelines Initiative Group on behalf of the Anxiety Disorders Association of Canada/Association Canadienne des troubles anxieux and McGill University (2014) · BMC Psychiatry · doi:10.1186/1471-244x-14-s1-s1 · Cited by 1,090
Bandelow, B., Zohar, J., Hollander, E., Kasper, S., Möller, H.-J., WFSBP TASK FORCE ON TREATMENT GUIDE, Bandelow, B., Zohar, J., Hollander, E., Kasper, S., et al. (2008) · The World Journal of Biological Psychiatry · doi:10.1080/15622970802465807 · Cited by 854
Treatment of anxiety disorders
Bandelow, B., Michaelis, S., & Wedekind, D. (2017) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2017.19.2/bbandelow · Cited by 811
Andrews, G., Bell, C., Boyce, P., Gale, C., Lampe, L., Marwat, O., Rapee, R., & Wilkins, G. (2018) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867418799453 · Cited by 243
“Three controlled studies have shown that short-term (4–6 weeks) addition of benzodiazepines (alprazolam or clonazepam) to antidepressants produces a more rapid response, although patients on alprazolam had difficulty discontinuing (Goddard et al., 2001; Pollack et al., 2001; Woods et al., 1992).”
BackgroundStrawn, J. R., Geracioti, L., Rajdev, N., Clemenza, K., & Levine, A. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1491966 · Cited by 214
“clonazepam in adults with panic disorder initiating sertraline observed more rapid stabilization when paired with clonazepam combined initiation with placebo [61].”
BackgroundBandelow, B., Allgulander, C., Baldwin, D. S., Costa, D. L. D. C., Denys, D., Dilbaz, N., Domschke, K., Eriksson, E., Fineberg, N. A., Hättenschwiler, J., et al. (2023) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2086295 · Cited by 158
Anxiety disorders: a comprehensive review of pharmacotherapies
Hoffman, E. J., & Mathew, S. J. (2008) · Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine · doi:10.1002/msj.20041 · Cited by 149
The reappraisal of benzodiazepines in the treatment of anxiety and related disorders
Starcevic, V. (2014) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.2014.963057 · Cited by 90
“In fact, a body of literature supports the use of this combination for quick alleviation of distress and panic symptoms and for producing an earlier response in the treatment of panic disorder [32,33] and for achieving a better outcome in the treatment of SAD [34].”
BackgroundStahl, S. M. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n0901 · Cited by 88
“On the other hand, GABAergic benzodiazepines may have a rapid onset of action and boost early efficacy of serotonergic agents (if sedation can be avoided), and then be discontinued after shortterm administration, thus serving as a bridge to long-term serotonergic treatments.(9) Benzodiazepines can also serve as emerge…”
BackgroundEvidence-based pharmacotherapy of panic disorder: an update
Batelaan, N. M., Van Balkom, A. J. L. M., & Stein, D. J. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000800 · Cited by 67
“To lower anxiety symptoms and to achieve a more rapid stabilization of panic symptoms, temporary addition of benzodiazepines during the initial phase of antidepressant treatment can also be considered (Goddard et al. 2001; Pollack et al. 2003).”
BackgroundTreatment-Resistant Panic Disorder
Bandelow, B., & Rüther, E. (2004) · CNS Spectrums · doi:10.1017/s1092852900022379 · Cited by 57
Benzodiazepines and anxiety disorders: a review for the practicing physician
Kaplan, E. M., & DuPont, R. L. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x48401 · Cited by 55
The Role of High-Potency Benzodiazepines in the Treatment of Panic Disorder
Susman, J., & Klee, B. (2005) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.v07n0101 · Cited by 39
“Efficacy of the early coadministration of SSRIs and the high-potency benzodiazepine clonazepam was fully examined in 2 double-blind studies.(44,45) In the Goddard et al.”
BackgroundEmerging drugs for panic disorder
Perna, G., Guerriero, G., & Caldirola, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.628313 · Cited by 23
“BDZs combined with SSRIs in the first week of treatment appeared to accelerate therapeutic response compared with SSRIs alone [39,40] and alleviate the initial increase of anxiety, even though there was no differential benefit beyond the initial few weeks of therapy.”
Background
Metadata
- Authors
- Goddard, A. W., Brouette, T., Almai, A., Jetty, P., Woods, S. W., & Charney, D.
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2001-07-01
- Volume
- 58
- Issue
- 7
- Pages
- 681
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W1976593460
- Cited by
- 156
- References
- 4
- FWCI
- 10.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.